COVID-19 has been a first-hand challenge for mankind since the beginning of 2020. Speedy research is currently underway and has led researchers to find a cure. Remdesivir drug is a popular name that you might have heard so far as it has been used to test COVID-19. Remdesivir has gone from tests as a possible cure for Ebola to provide modest benefits to people with COVID-19. Gilead Science Inc. launched remdesivir research in 2009. Remdesivir was originally developed for the treatment of hepatitis C virus. Among the many antiviral drugs tested are remdesivir, favipiravir and merimepodib. Hydroxychloroquine, chloroquine, lopinavir and ritonavir are ineffective. Research continues on drugs such as amlodipine, ivermectin, losartan, and famotidine. However, the extent to which these drugs can be effective in the treatment or prevention of COVID-19 is still not understood.

Remdesivir is being tested as a COVID-19 treatment and has been authorized for emergency use in the USA, India, Singapore and approved for use in people with severe symptoms in Japan, EU, UK and Australia. Remdesivir demonstrated in vitro and in vivo activity against the viral pathogens MERS and SARS, both coronaviruses and structurally similar to COVID-19. It has recently been found that the drug has not increased recovery times or decreased mortality relative to those taking placebo. Only moderate remdesivir benefits against COVID-19 have been identified. The side effects of remdesivir in the COVID-19 studies include respiratory failure and organ impairment, including low albumin levels, low potassium levels, low red blood cell counts, low platelet counts, and yellow discolouration of the skin. In conclusion, remdesivir is still an experimental drug. Earlier treatment with remedesvir in patients, and combination therapy might work better.